Abstract 62P
Background
According to the GLOBOCAN database 2020, colorectal cancer (CRC) has the fourth-highest incidence in Indonesia. In Yogyakarta province, CRC is the third most prevalent cancer. CRC usually present with common gastrointestinal complaints. The relationship between the chief complaint and clinicopathology parameters has been rarely explored in Indonesia. We, therefore, aimed to analyze their association with our CRC patients.
Methods
A retrospective study was done on 1,276 CRC cases diagnosed between January 2016 and December 2019 at Dr. Sardjito Hospital, Yogyakarta. We collected secondary data from the CRC clinical registry database, including demography, chief complaints and clinicopathology features. Data on hospitals where CRC diagnostic procedure was performed based on biopsy or resection. Chi-square analysis was used to determine the relationship between the chief complaint and clinicopathology parameters.
Results
The most common chief complaints were hematochezia (34.4.%), bloating (24.8%), constipation (23%), diarrhea (17.5%), weight loss (12.1%) and abdominal mass (9.8%). Hematochezia was associated with tumor site, T status, N status, M status, clinical stage, performance status, and type of diagnostic hospital. Diarrhea was associated with age, hemoglobin, serum albumin, and type of diagnostic hospital. Constipation was associated with gender, tumor site, N status, serum albumin, and type of diagnostic hospital. Bloating was associated with tumor site, M status, clinical stage, histological grade, serum albumin, performance status, and type of diagnostic hospital. Weight loss was related to the tumor site, M status and diagnostic hospital. Abdominal mass was associated with age, gender, and serum albumin. All p values were < 0.05.
Conclusions
The chief complaints of CRC were associated with various clinicopathological parameters that may influence the patient's prognosis. Because complaints associated with CRC are similar to other gastrointestinal diseases, the awareness of clinicians to immediately follow up is needed so that patients can be identified at an earlier stage. Referral process across hospitals may also serve as a target for health system improvement.
Clinical trial identification
Editorial acknowledgement
The authors thank Yana Suryani, Rosita Yunanda Purwanto, and Nugira Dinantia for technical assistance and coordination.
Legal entity responsible for the study
Yasjudan Rastrama Putra.
Funding
The authors received financial support from the Applied Research Grant 2020–2021, The Indonesian Ministry of Research, Technology, and Higher Education and the Institutional Links grant, ID 527558574, under the Newton Institutional Link-Indonesia KLN Fund partnership, funded by the UK Department for Business, Energy and Industrial Strategy and Indonesia Ministry of Research Technology & Higher Education and delivered by the British Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
94P - The treatment burden of neoadjuvant carboplatin/paclitaxel versus 5-fluorouracil/cisplatin in combination with radiotherapy for patients with esophageal cancer
Presenter: Chun-Ling Chi
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
96P - Preoperative chemotherapy flot vs dox in patients of locally advanced gastric adenocarcinoma
Presenter: POORNIMA DEVI UTHAYAKUMAR
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02